Clinical spectrum of myasthenia gravis: An institute... : Journal of Family Medicine and Primary Care
nvolving all myasthenia patients presenting to neurology and cardio-thoracic department from the year 2013 to 2020. The clinical findings, Osserman grade of severity, antibodies profile, computed scanning thorax findings and...
Conclusion: MG is a treatable autoimmune disorder with a variety of clinical, radiological, and histopathological findings.
COVID-19-associated AMPA-R and CRMP-5 autoimmune encephalitis in a patient with thymoma and myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36950670/
Thymomas are associated with autoimmune disease, most commonly myasthenia gravis, and rarely with autoimmune encephalitis. More recently, viral triggers including COVID-19 have also been implicated in autoimmunity. We present a...
Discussion: Here, we present a case of a patient with pre-existing thymoma and MG who developed AMPA-R/CRMP-5 receptor autoimmune encephalitis in the setting of SARS-CoV-2 infection ….
PINK1/Parkin pathway-mediated mitophagy by AS-IV to explore the molecular mechanism of muscle cell damage
Source : https://www.sciencedirect.com/science/article/pii/S0753332223003219?via=ihub
The combination of CCCP and H 2O 2 can induce excessive mitophagy. * AS-IV can reduce excessive mitophagy through the PINK1/Parkin pathway. * AS-IV can improve L6 cells damage and...
Conclusion: AS-IV is a potential drug for myasthenia gravis (MG), and its treatment mechanism is related to mediating mitophagy and restoring mitochondrial function through the PINK1/Parkin pathway.
Effects of comorbid diseases on clinical outcomes in patients with myasthenia gravis - Neurological Sciences
Source : https://link.springer.com/article/10.1007/s10072-023-06750-8
Background This cross-sectional study was undertaken to evaluate the existence and distribution of comorbid disorders among myasthenia gravis (MG) patients according to subgroups and to identify the effects of the...
Conclusion: Hypertension and type 2 DM had negative effects on the clinical outcomes of MG.
Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-023-03162-1
Background This study aimed to investigate the clinical risk factors of dysautonomic symptom burden in neuromyelitis optica spectrum disorder (NMOSD) and its impact on patients' quality of life. Methods A...
Conclusions: Dysautonomic symptom burden is correlated with decreased quality of life and certain clinical characteristics such as disability, the burden of spinal cord lesions, and fatigue in NMOSD patients. Investigation and proper management of autonomic dysfunction may help to improve the quality of life in patients with NMOSD.